Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.
Key Topics Include:
- Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
- Describe how CMS will determine fair market prices for Medicare Part D drugs
- Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements
Director, Client Engagement
Pricing, Market Access and Reimbursement
Head of Business Intelligence
VP, Scientific Affairs
Oncology Medical Strategy
VP, PMAC Consulting
Patient Insight, Market Access and Commercial
Global Health Economics and Outcomes Research